The FDA cleared PrecivityAD2, a blood test designed to help detect biological evidence associated with Alzheimer’s disease, providing clinicians with a less invasive tool that may assist in the evaluation of patients experiencing cognitive symptoms. The test measures specific biomarkers associated with Alzheimer’s pathology and is intended to complement clinical evaluation rather than replace a comprehensive diagnostic assessment. The clearance represents continued progress toward accessible blood-based Alzheimer’s testing and could help expand the use of biomarker-based approaches in the diagnosis and management of the disease.
